Ionis Pharmaceuticals IONS Liability Related To Sale Of Future Royalties Net Noncurrent
Liability Related To Sale Of Future Royalties Net Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's liability related to sale of future royalties net noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's liability related to sale of future royalties net noncurrent?
- Ionis Pharmaceuticals (IONS) reported liability related to sale of future royalties net noncurrent of $557.77M in Q1 2026.
- How has Ionis Pharmaceuticals's liability related to sale of future royalties net noncurrent changed year-over-year?
- Ionis Pharmaceuticals's liability related to sale of future royalties net noncurrent increased by 4.0% year-over-year, from $536.14M to $557.77M.
- What does liability related to sale of future royalties net noncurrent mean?
- Debt owed to investors based on future royalty payments sold in exchange for immediate cash.
- How do you interpret liability related to sale of future royalties net noncurrent?
- An increase indicates the company has monetized future assets for immediate capital, which may reduce future cash flow margins.
- How does liability related to sale of future royalties net noncurrent compare across companies?
- Specific to pharmaceutical and biotech companies that use royalty monetization as a non-dilutive funding strategy.